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Summary  
Therapy of haemophilia has undergone very rapid evolution in the past 10 years. The major 
limitation of current replacement therapy is the short half-life of factors VIII and IX. These half-lives 
have been extended by addition of various moieties, allowing less frequent infusion regimens. 
Entirely novel approaches have also entered the clinic including a bispecific antibody that mimics 
factor VIII and strategies that rebalance the haemostatic mechanism by reducing antithrombin 
through inhibition of synthesis. These two treatments are available by subcutaneous injection at 
infrequent intervals and both can be used in patients with neutralising antibodies (inhibitors). 
Finally, a cure may be on the horizon with preliminary evidence of success for gene therapy in 
haemophilia B and A. 
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Introduction  
Haemophilia A and B are X-linked, monogenic bleeding disorders due to factor VIII (FVIII) deficiency 
and factor IX (FIX) deficiency respectively. Approximately 1/5000 males are affected with 
haemophilia A, with 1/30000 males in haemophilia B (Mannucci & Tuddenham 2001; Bolton-Maggs 
& Pasi 2003). In its severe form, spontaneous bleeding occurs from a young age, typically in the form 
of haemarthroses and skeletal muscle haematomas in the absence of antecedent trauma, resulting 
in chronic arthropathy with significant deformities in the long term if untreated. In the pre-clotting 
factor concentrate era, death in both conditions was primarily due to intracranial haemorrhage or 
other life threatening bleeds and patients rarely survived beyond 10 years. Prophylactic 
administration of factor concentrate to maintain circulating factor levels above 1IU/dL (1%) of 
normal has resulted in a dramatic reduction in bleeding frequency and its associated complications, 
with substantial improvements to life expectancy over recent decades (Darby et al. 2007). 
In the last forty years, treatment has largely focused on incremental changes progressing from using 
cryoprecipitate (for haemophilia A) or whole plasma (for haemophilia A or B) to plasma derived and 
more recently, recombinant specific factor concentrates. Treatment based on cryoprecipitate 
transfusion was rich in FVIII, and was in routine use until the 1970s (Mannucci 2002).  Developments 
were made to move towards factor concentrates to deliver a more consistent dose compared with 
cryoprecipitate, as well as significantly improving safety of concentrates through viral inactivation 
steps by heat, solvent detergent and nanofiltration methods.   
Despite significant improvements to ensure safety, there are disadvantages with current clotting 
factor replacement. Inhibitor formation (neutralising allo-antibodies which form against factor 
concentrate) causes significant morbidity for patients, which affects 20-45% with severe haemophilia 
A and 3% of haemophilia B who are previously untreated patients (PUPs) (Astermark et al. 2010, 
Peyvandi et al. 2016). Immune tolerance induction regimens (ITI) are used to eradicate the inhibitor, 
but can take several months or years, and are only effective in haemophilia A. While 80% respond to 
this treatment with resolution of the inhibitor, ITI is highly expensive as it requires very high doses of 
concentrate to succeed (50-200U/kg alternate days or daily) (Collins et al. 2013). At least 20% of 
patients are resistant to ITI with long term consequences for their health due to hitherto only partly 
successful agents for bypassing FVIII or FIX deficiency in the presence of neutralising antibody. To 
reduce the risk of inhibitor formation, some haemophilia centres elect to use plasma derived 
concentrates for previously untreated patients (PUPs) which may have lower inhibitor risks 
compared with recombinant products. The SIPPET study which recruited children showed that in 
PUPs the use of recombinant FVIII had an 87% increase in risk of inhibitor formation rates compared 
with plasma derived products (Peyvandi et al. 2016). However, the use of plasma derived products 
does not eliminate the risk of viral transmission nor of prions causing variant Creutzfeldt-Jakob 
Disease.  
Pharmacokinetics in each individual varies and therefore standardised dosing may result in patients 
being undertreated if factor clearance is higher than expected. Routine primary prophylaxis for 
patients with severe haemophilia A is offered on alternate days in the United Kingdom and for 
severe haemophilia B every 3-4 days. For haemophilia A, FVIII concentrate dosing is recommended 
on the basis of a half-life of 8-12 hours (Srivastava et al. 2013), but large patient cohorts studied 
suggest that FVIII half-life has a much wider range, estimated between 6-25 hours (Björkman et al. 
2009; Björkman et al. 2010). Patients with levels which routinely fall below 1U/dL are at risk of 
increased bleeding (Collins et al. 2009). Variation in personal lifestyles or bleeding phenotypes may 
mean patients require different trough level targets. To account for these variations, clinicians may 
elect to do individualised pharmacokinetic studies and the results could reduce costs of treatment 
with increased frequency of dosing (Collins 2012). Caution in interpreting results is required given 
challenges with accurate factor level measurement, with differing levels reported between 1-stage 
and chromogenic assays for standard half-life and extended half-life concentrates (Kitchen et al. 
2014). 
Factor concentrates remain highly expensive even with national contract negotiation (O'mahony et 
al. 2015) and stretch national health budgets, while being unaffordable in less economically 
developed countries. Prophylactic treatment to reduce mortality and improve quality of life is 
therefore beyond the means of many haemophilia patients across the world. Support for 
haemophilia patients in the form of regular medical reviews is also lacking in many under resourced 
areas.  
 
The last decade of research in haemophilia has yielded many potentially life-changing therapies with 
exciting novel treatments such as RNA silencing agents (siRNA), FVIII mimetics and gene therapy 
which are currently in clinical trials and show great promise. There remains a significant unmet 
medical need to improve self-care, reduce requirements for venous access and frequency of dosing, 
reduce or eliminate inhibitor risk and ultimately devise a cure for this condition. In this review, we 
summarise recent advances in haemophilia treatment and current clinical progress made in these 
areas.   
 
Factor concentrates  
Half-life extension has been an important evolution in concentrate manufacturing to enable patients 
to reduce the frequency of dosing with better maintenance of factor levels, especially higher trough 
levels. This has been more successful in haemophilia B than in haemophilia A (where the half-life is 
dominated by that of its carrier – von Willebrand Factor). Table 1 lists recently licensed FVIII and FIX 
concentrates or those with completed clinical trials. Historically, standard half-life FVIII concentrates 
were first to be commercially available, followed by FIX products but in recent years extended half-
life concentrates (EHLs) for haemophilia B have been developed more quickly, with clinically 
significant increases over standard half-life FIX concentrates of 2.4-4.8 fold (Young & Mahlangu 
2016). Previously published trial data on EHLs has been collated into a review for clinicians to choose 
an option that would be best suited for their patients as per recommendations issued by the United 
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Pegylation of FIX CHO 96.3 Licensed (Collins, Young, et 
al. 2014) 
Table 1 – list of new FVIII/FIX standard and EHL concentrates. Italics denote fourth generation 
concentrates.  
FIX concentrates 
EHL FIX concentrates have enabled dosing frequency in haemophilia B to be reduced from 
approximately twice weekly to once every 7-14 days (Collins et al. 2016). Three FIX products have 
completed Phase 3 clinical trials in haemophilia B patients, with each using different methods to 
prolong circulating FIX levels. rFIX-Fc (Alprolix, Biogen) fuses the Fc immunoglobulin region with FIX, 
while rFIX-FP (Idelvion, CSL Behring) combines FIX with albumin, and nonacog beta pegol (N9-GP, 
Novo Nordisk) is a pegylated version of FIX. Despite the differing products from a manufacturing 
perspective, haemostatic efficacy was reported at similar levels, with all three products requiring 1-2 
injections for bleed resolution and an overall efficacy of between 96.7-97.2%. Median annual 
bleeding rates (ABR) were estimated at between 0-3.0 for all three products. (Santagostino et al. 
2016; Collins, Young, et al. 2014; Young & Mahlangu 2016). 
FVIII concentrates 
FVIII EHLs have yielded less progress with half-life prolongation of 1.5 times compared with standard 
FVIII concentrates (Mahlangu et al. 2014; Young & Mahlangu 2016). As with FIX EHLs, Fc fusion or 
pegylation has been used to produce FVIII EHLs, with half-lives of new products ranging from 14.3-19 
hours. Because of this modest extension in half-life, subject to pharmacokinetic analysis for 
individualised dosing, it is recommended to suggest a reduction in frequency of dosing from 
alternate days to once every 3-4 days (Collins et al. 2016). The relative lack of improvement in half 
life in FVIII concentrates are thought to be related to the interaction of FVIII with vWF. In a few 
patients, no increase in the interval dosing is seen when an EHL is used compared with a standard 
product (Makris 2012; Tang et al. 2013; Croteau & Neufeld 2015). 
Manufacturers have continued to produce new versions of recombinant standard half-life 
concentrates with putative improvements in their manufacturing process. Table 2 lists the different 
generations of products and their characteristics. Increasingly, the trend has been towards 
eliminating human or animal plasma derived proteins in large scale manufacturing to reduce, as far 
as possible, risks of as yet unidentified viruses to ensure the highest level of safety.   
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No No Advate, Refacto AF, NovoEight, Kovaltry 
Fourth 
generation  
Human (HEK)  No No Nuwiq 
Table 2. Standard half-life recombinant FVIII concentrates   
Two new, third generation concentrates have been produced: BAY81-8973 (Kovaltry, Bayer), a full 
length FVIII, is based on the same sequence as octocog alfa, a second generation concentrate 
(Kogenate FS, Bayer) but with the removal of human or animal proteins in its manufacture apart 
from the use of a baby hamster kidney (BHK) cell line (Keating 2016). Turoctocog alfa (NovoEight, 
Novo Nordisk) is a B-domain truncated FVIII, with the B domain specifically designed to 
accommodate pegylation. The sequence in this FVIII product has been used to develop a pegylated 
FVIII, Turoctocog alfa pegol (N8-GP, Novo Nordisk) as an EHL.  
Fourth generation concentrates have also been in clinical trials with the aim of reducing inhibitor 
formation. This differs from third generation concentrates by using human instead of animal cell 
lines for production, with further potential to reduce immunogenicity. Simoctocog alfa (Nuwiq, 
Octapharma) is currently the only fourth generation, standard half-life concentrate produced with 
human embryonic kidney (HEK) cells and post-translational modifications are designed to be similar 
to plasma derived FVIII. A multicentre, open-label Phase 3 trial in 32 adults in a standard prophylaxis 
regime for ≥6 months who were severe previously treated patients (PTPs) showed mean ABRs of 
2.28 for all bleeds, 1.16 for spontaneous bleeds and 1.00 for traumatic bleeds. Biochemical in vitro 
analysis showed normal restoration of thrombin generation, and no discrepancy between 1-stage 
APTT based and chromogenic assays.  A further phase 3 study is still under recruitment for PUPs 
(Liesner et al. 2016), however participation rate had not yet reached the stage of 50 EDs to inform 
on inhibitor rates compared with other currently licensed products.   
 
Non-clotting factor based therapies  
Alternative approaches using methods beyond clotting factor replacements have been developed, 
primarily with the aim of restoring haemostasis through bypassing the deficient coagulation protein. 
Table 3 summarises the approaches, of which two methods aim to inhibit proteins that are 
themselves inhibitors of the coagulation pathways, thus targeting both haemophilia A and B patients 
(a monoclonal anti-TFPI antibody and a small interfering RNA (siRNA) molecule to reduce 
antithrombin levels), and the use of an antibody to mimic the activity of FVIII as a co-enzyme for 
haemophilia A. These alternative approaches have efficacy in patients with inhibitors who do not 
respond to conventional clotting factor replacement. These newer agents also are amenable to the 
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washout period post injection 
One fatal thrombosis reported in use of fitusiran 
with FVIII concentrate used for breakthrough 









Subcutaneous dosing for 
easier administration 
Suitable for patients with FVIII 
inhibitors 
Effective in both haemophilia 
A and B 
Early evidence of non-linear pharmacokinetics in 
animal models  




Once weekly, subcutaneous 
injection  
Suitable for patients with FVIII 
inhibitors  
Not suitable for patients with Haemophilia B  
Early trials have shown adverse events in 
combination with activated protein C 
concentrates 
Table 3. Non-clotting factor based therapies and their mechanisms.  
 
Antithrombin targeting   
A strategy to rebalance the haemostatic system in patients with haemophilia, who have defective 
procoagulant pathways, works to reduce their natural inhibitor of thrombin generation. 
Antithrombin (AT) is a serine proteinase inhibitor in the serpin family, and acts in the coagulation 
system by primarily inhibiting thrombin, Factor Xa (FXa) and Factor IXa (FIXa) through irreversible 
neutralisation. AT is a key protein in the haemostatic pathway for regulating normal haemostasis, as 
AT deficiency either in congenital or acquired forms is the highest risk factor for thromboembolic 
disease (Menache et al. 1992). 
Small interfering RNA sequences (siRNA) have been used to target AT by binding with AT mRNA 
produced by the hepatocyte. Fitusiran is a double stranded RNA molecule which inhibits and 
degrades AT mRNA and in turn reduces AT levels. As AT inhibits FXa, the reduction in AT potentiates 
the effect of the procoagulant pathway to restore normal haemostasis. A phase I trial targeting 
healthy volunteers injected 45ug/kg doses weekly for three weeks and noted a trough AT level at 28 
days with an increase in thrombin generation by 334% (Sorensen et al. 2014).  
A completed phase I dose-escalation study (NCT02035605) was performed looking at 4 healthy 
volunteers and 25 patients with moderate or severe haemophilia A or B without inhibitors, at 
varying doses of administration (healthy volunteers received 0.03mg/kg or placebo, while 
haemophilia participants received 0.015-0.075mg/kg in weekly doses or 0.225-1.8mg/kg or 80mg in 
monthly dosing). Initial trial results were promising with mean maximum antithrombin reduction of 
70-89% from baseline, with a fall in mean ABR (at all doses) from 9.7 to 5.4 at 29-56 days post last 
dose. Increase in thrombin generation correlated with decreases in antithrombin level, with median 
peak thrombin levels at the lower end of the range observed in healthy volunteers, for haemophilia 
participants who had >75% AT reduction from baseline. No serious adverse events were recorded 
(Pasi et al. 2017). However, in a Phase 1/2 extension study (NCT02554773) a fatal thrombosis was 
announced by Alnylam in a press release in September 2017. The patient in question while on 
fitusiran had received three doses of FVIII concentrate therapy (31-46IU/kg each dose) over three 
days for exercise induced hip pain when he developed a headache after the third dose. The 
headache was judged to be secondary to a subarachnoid haemorrhage based on CT imaging, and the 
patient continued to receive FVIII concentrate 2-3 times daily with deterioration in his clinical status 
until death from cerebral oedema. Further analysis suggested that the precipitating event for the 
intracranial bleed was because of a cerebral venous sinus thrombosis. All further trials with fitusiran 
have been suspended while safety investigations are in progress. 
 
TFPI inhibition 
Tissue factor pathway inhibitor (TFPI) is a multivalent, Kunitz-type proteinase inhibitor (KPI) with 
three KPI domains, and functions by inhibiting generation of FXa and the activity of the TF/FVIIa 
complex (Broze & Girard 2012). Inhibition of TFPI downregulates the negative feedback loop that 
regulates tissue factor (TF)/FVIIa–mediated Factor X (FX) activation during the initiation phase of 
coagulation. Blockage of TFPI inhibition aims to restore TF/FVIIa-mediated FXa generation that is 
sufficient for haemostasis.  
Concizumab (mAb 2021), a monoclonal antibody was designed to inhibit KPI domain 2 on TFPI which 
is known to bind FXa. In a study by Hilden et al. investigating in vitro and in vivo effects, the addition 
of mAb 2021 to haemophilic plasma and whole blood shortened clot times in a dilute PT assay and 
improved thrombin generation. In a transient rabbit haemophilia model induced by FVIII antibodies, 
mAb 2021 was given at doses from 0.5-8mg/kg. Bleeding volumes for doses 1mg/kg reduced 
bleeding compared with rabbit haemophilia controls, and were not significantly different from 
normal rabbit controls. At doses of 10mg/kg, subcutaneous injection in rabbits was also shown to be 
effective (Hilden et al. 2012). 
A human phase 1 dose finding study was conducted in both healthy volunteers (n=28) and 
haemophilia patients (n=24) with concizumab injected both intravenously and subcutaneously. 
Three adverse events were reported in those receiving concizumab, one episode of superficial 
thrombophlebitis which resolved spontaneously and one of transient proteinuria and another of 
abdominal pain. No clinically relevant changes in platelets, PT, aPTT, fibrinogen, or antithrombin 
were found. Non-linear pharmacokinetics were noted and a dose-dependent procoagulant effect of 
concizumab was seen as increased levels of D-dimers and prothrombin fragment 1 + 2. No cases of 
thrombosis were observed (Chowdary et al. 2015). In a separate ex-vivo spiking study, platelet poor 
plasma from haemophilia patients was spiked with concizumab. At doses of 10nM, thrombin 
generation approached near those of healthy controls (Waters et al. 2017). Two Phase 2 trials are 
yet to open investigating the effect of concizumab on haemophilic patients with and without 
inhibitors (registered trials NCT03196284 and NCT03196297 respectively).  
 
FVIII co-enzyme mimetics 
Emicizumab, currently in Phase 3 trials, is a humanised, IgG4 antibody designed to have the same 
functional characteristics as activated FVIII (FVIIIa). The antibody functions in a bispecific format by 
binding FIXa to one arm of the antibody and FX to the other, accelerating the activation of the FX 
zymogen to FXa, thus propagating further thrombin generation. An antibody which closely mimics 
the activity of FVIIIa, can bypass any inhibitors to FVIII, and carries a further significant advantage as 
delivery is by subcutaneous injection rather than intravenous infusion. 
A Phase I trial with an initial loading dose of 1mg/kg, followed by one of 0.3mg/kg, 1mg/kg or 
3mg/kg weekly for 12 weeks was carried out in severe haemophilia A patients with and without 
inhibitors. In 18 patients (6 at each dose), all dosing levels showed a reduction in median ABR from 
32.5 to 4.4, 18.3 to 0, and 15.2 to 0 respectively. In 8 of 11 patients with inhibitors, no bleeding 
occurred, with an accompanying reduction in use of clotting factors to stop bleeding and no 
identified antibodies to emicizumab (Shima et al. 2016). 
Phase 3 trials with emicizumab have commenced and are continuing. HAVEN 1 has completed 
recruitment (n=109) in patients with inhibitors 12 years and older. Patients were divided into three 
arms (emicizumab, no emicizumab and emicizumab with previous history of bypassing agent 
prophylaxis). 63% of patients on emicizumab reported no bleeds on the trial, with an overall 
reduction in bleed rate of 87% compared with the no emicizumab arm, with accompanying 
improvements in health status and quality of life assessments (P<0.001). Those who had 
prophylactic bypassing agents previously and now on emicizumab prophylaxis had a bleeding rate 
that fell by 79%.  
15% of patients receiving the drug reported injection site reactions. Five patients developed major 
adverse events during the Phase 3 trial, all with concomitant use of activated protein complex 
concentrate (aPCC) to stop active bleeds (two episodes of thrombosis and three incidents of 
thrombotic microangiopathy). One death occurred from the five patients with a major AE reported 
but was judged to be unrelated to emicizumab administration, and two of these five patients 
successfully restarted emicizumab with no further side effects (Oldenburg et al. 2017). Preliminary 
work on characterising the thrombogenicity of emicizumab have started with ROTEM analysis on 
citrated, whole blood samples of haemophilia patients. Ex-vivo spiking of emicizumab and a 
bypassing agent (either rFVIIa or aPCC) significantly decrease the clot time (CT) and clot formation 
time (CFT) compared with emicizumab alone, with aPCC showing greater shortening of CT and CFT 
compared with rFVIIa (Yada et al. 2017). This may underline concerns that an unregulated FVIII 
mimic which functions in a permanently active state produces a deregulated and intrinsically 
unstable thrombin generation system, with more investigation required on the causes of 
thrombogenicity. Additional data suggest that emicizumab lacks the ability to function in the 
absence of phospholipid binding and has a much lower binding affinity compared with FVIII to FIXa 
and FX (Kitazawa et al. 2017) which may compensate for the permanently ‘switched on’ activity.  
Subsequent trial protocol amendments have prohibited the use of aPCC with emicizumab to prevent 
further serious adverse events.  
More phase 3 trials are underway, with HAVEN 2 (NCT02795767) targeting inhibitor patients aged 
less than 12 years old, with further studies to investigate non-inhibitor patients (HAVEN 3, 
NCT02847637) and reductions in dosing frequency to fortnightly or monthly (HAVEN 4, 
NCT03020160).  
 
Gene therapy  
A one-time intravenous infusion to treat haemophilia permanently is a paradigm-shifting therapy for 
patients. Current treatment, because of its expense and pharmacodynamics, has meant that 
prophylactic factor concentrate treatment had only the modest goal of keeping trough levels of factor 
just above 1IU/dL to stop major acute bleeding and its chronic sequelae. Fairly recent data, by the 
simple but effective means of studying patients with mild haemophilia, clearly demonstrated that 
bleeding in joints is only completely eliminated at levels of 15IU/dL or more (Uijl et al. 2010). 
Even in its extended half life forms, clotting factor replacement (as described above) requires repeated 
intravenous infusions, although injections are required less frequently. Replacement factor therapy 
necessitates interval dosing which comes with peaks and troughs of factor levels; when these trough 
levels are insufficiently high this results in occasional breakthrough bleeds. 
Both haemophilia A and B are ideal candidates for gene therapy; a small increase in factor levels can 
substantially ameliorate the bleeding phenotype. Gene therapy has had a resurgence of interest for 
its curative potential in many conditions but previously had its setbacks; initial trials in 2002 in severe 
combined immunodeficiency successfully treated the condition, but the use of an oncoretroviral 
vector inevitably led to insertion of the transgene into the host genome, which in a tiny proportion of 
insertions upstream of the LMO2 gene in some recipients caused a leukaemia like syndrome (Thomas 
et al. 2003). Safety has therefore been a key concern of subsequent trials since.  
In haemophilia, adeno-associated virus (AAV) is the vector of choice, selected for its lack of 
pathogenicity in humans in that the majority of viral DNA is not integrated into the host genome and 
remains episomal, thus reducing likelihood of oncogenesis and germ line transmission. Currently, 
there remain hypothetical risks to tumourigenesis with AAV gene therapy despite an absence of 
oncogenic events in over 130 AAV gene therapy studies. Low level of integration has been observed 
with wild-type AAV viruses, estimated at 0.1% of virus transduction for chromosome 19 specific 
integration, a site of known predilection for AAV integration (Huser et al. 2002). More recent findings 
have identified clonal integration of AAV2 in hepatocellular carcinoma (HCC) samples in 11 out of 193 
cases studied, which have upregulated cancer driver genes (CCNA2, TERT, CCNE1, TNFSF10, KMT2B) 
(Nault et al. 2015). Notably among the 11 AAV-positive biopsies, 5 biopsies presented with other well-
known HCC-driving conditions (such as alcohol consumption or hepatitis B or C infections) and 4 
biopsies presented with AAV-unrelated mutations which have been previously linked with liver cancer 
development (such as TP53 or AXIN1). 
Current participants recruited to trials have been limited to adult populations for whom the liver is 
fully developed, such that effective hepatocyte transduction is not lost in mitotically active and 
growing liver tissue. Patients identified as suitable for AAV gene therapy must be seronegative for 
antibodies to the specific capsid used. Anti-AAV antibodies across all serotypes are estimated at 10-
80%, but some serotypes such as AAV5 (10-20%) and AAV8 (10-30%) have less population immunity 
compared with AAV2 (up to 70%) which has historically been the most frequently studied (Halbert et 
al. 2006, Calcedo et al. 2009, Mingozzi et al. 2013), and thus switching capsids may provide a solution 
to increasing access for patients to gene therapy. A summary of current trials conducted in 
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Table 4. Summary of gene therapy trials in Haemophilia A and B.   
 
Haemophilia B  
The first successful study in severe haemophilia B patients showed sustained FIX expression in a cohort 
of 10 patients, while studies prior to this used a variety of vectors resulting in only transient increases 
in patients’ factor levels before returning to baseline (Nathwani et al. 2011; Nathwani et al. 2014; 
Lheriteau et al. 2015). To overcome difficulties observed in previous trials, the FIX gene was codon 
optimised, such that the codon sequence of each amino acid was modified to reflect sequences of 
human proteins that were highly expressed in the human liver. In addition, a FIX self-complementary 
sequence enabled one virion to have both the coding and complementary sequence such that the 
transgene can become readily transcriptionally active. Finally, a pseudotyped vector was used with an 
AAV2 genome but with the AAV8 capsid, which has increased liver tropism and reduced antibody 
seroprevalence in humans compared with other serotypes of AAV (Sands 2011; Boutin et al. 2010). 
Patients were enrolled to this Phase I study at low, intermediate and high vector doses, producing 
sustained FIX:C expression at 1–6IU/dL in all ten subjects during a follow-up period extending to a 
median of 6 years, concomitant with decrease in FIX concentrate usage by 90%. The most promising 
current trial sponsored by Spark Therapeutics and Pfizer have used a novel engineered AAV capsid, 
with a FIX Padua transgene which is known to demonstrate 8-fold higher activity and demonstrates a 
thrombophilic tendency in patients with otherwise normal coagulation states, compared with wild-
type FIX (Simioni et al. 2009). In 10 patients, mean FIX:C levels of 29IU/dL were achieved in those 
reaching 12 weeks of follow-up (George et al. 2016). 
Haemophilia A 
Although haemophilia A is 5 times more prevalent than haemophilia B and therefore the more obvious 
candidate for gene therapy, the cDNA size of the FVIII gene has been a hurdle to developing an 
expression cassette that is packageable into an AAV vector for FVIII production. The FVIII full length 
cDNA is 7 kilobases (kb) long compared with the FIX cDNA of 1.5kb; and a B-domain deleted form of 
FVIII cDNA is 4.4kb. Typically, AAV can package up to 4.6-5kb, which leaves little room for regulatory 
elements of the virus (Lheriteau et al. 2015). Sequences greater than 5kb in size have been used 
successfully but in vivo potency of the transgene was reduced by 2-3 fold (Dong et al. 2008; Chen et 
al. 2009). 
With additional technical challenges to overcome, clinical trials in haemophilia A have thus lagged 
those of haemophilia B. The transgene used has been either a B-domain deleted or truncated FVIII to 
reduce expression cassette size, with adjustments in the regulatory sequences to further minimise 
total size. Four trials are currently in the recruitment phase using different capsids and promoters (see 
Table 4). BMN270 (BioMarin) has conducted the first trial with an AAV5 capsid containing a B domain 
deleted FVIII sequence (SQ). Phase I recruitment has been completed. 15 patients were treated at 
doses ranging from 6e12 vector genomes (vg)/kg to 6e13vg/kg. Patients that received the highest dose 
of 6e13vg/kg (n=7) achieved mean FVIII:C levels of 116-129IU/dL with durable responses lasting 
greater than 52 weeks. A subsequent slightly lower dose 4e13vg/kg cohort (n=6) reached 31-42IU/dL 
at 12 weeks. Mean ABR changed from 17 to 0 for patients previously on prophylaxis, with mean 
annualised FVIII infusion rates falling from 139 to 0. 7. Subjects have all had a grade 1 transient 
elevation in ALT which was resolved with corticosteroids (Pasi et al. 2017). Three other trials now 
recruiting are using different capsid and FVIII variations.   
 
Therapeutic monitoring strategies 
There are existing challenges in current methods of factor level monitoring post concentrate 
treatment, which can vary significantly depending on the concentrate and assay used, with inter-
laboratory results showing considerable differences (CVs of 15-26% with chromogenic assays and 12-
19% in one stage assays) (Kitchen et al. 2016). In gene therapy, transgenes with engineered F8 or F9 
may present similar issues, as secreted FVIII or FIX may differ from currently available concentrates. 
EHLs also pose a challenge with FIX EHLs showing inter-laboratory variation of up to 161% against the 
International Standard defined by the Scientific and Standardization Committee (SSC), while one-stage 
FVIII:C and FIX:C results with EHLs are heavily dependent on the type of assays used (Kitchen et al. 
2014).  
As patients transition to non-clotting factor therapies, treatment monitoring and establishing 
‘equivalence’ to FVIII:C or FIX:C will become an increasing problem, as uncertainty surrounds the issue 
of how clinicians determine adequate prophylaxis aside from a bleeding history assessment. In FVIIIa 
mimetics, considerable discrepancy exists between the measurement of their activity by 1 stage 
clotting assays, chromogenic assays and thrombin generation (Goodman et al. 2017), even as FVIII:C 
monitoring by chromogenic assay shows a linear relationship with emicizumab concentrations 
(Adamkewicz et al. 2017). As anti-TFPI and anti-AT therapies work on a very different part of the 
coagulation cascade, correlation with a patient’s past treatment modalities will be even more 
complex. Monitoring patients on different therapies will require novel strategies and standardisation. 
Clinical laboratories will need to adapt to new methods; only then can there be informed assessment 
of breakthrough bleeding at patient reviews. 
 
Future therapies 
Innovative strategies which have not yet reached the stage of clinical trials revolve largely around 
three areas.  
Firstly, in haemophilia A, attempts are being made to extend the half-life of FVIII by improving FVIII-
vWF interaction. Previous work has shown that expression or infusion of the D’D3 region of vWF is 
sufficient to stabilise and prolong half-life of FVIII in vWF knockout mice, with a fusion D’D3 vWF-Fc 
protein demonstrating significantly longer half-life than a D’D3 synthetic vWF fragment alone (Yee et 
al. 2014). By making use of the FVIII-vWF interaction, strategies may be designed to co-infuse 
recombinant vWF, or FVIII variants with stronger affinity to vWF. Pestel et al. have used recombinant 
D’D3-albumin fusion protein and co-infused this with FVIII-SingleChain (CSL Behring) into 
haemophilia knockout mice, rats and rabbits which improved the half-life of FVIII to at least 1.5-3 
fold (Pestel et al. 2017). Kawecki et al. used a different approach by developing a bivalent nanobody 
which binds both vWF and albumin which extends half-life of vWF by 8-fold and FVIII by 6-fold at 7 
days in wild type C57Bl6 mice (Kawecki et al. 2017).  
Secondly, work on non-clotting factor replacements to haemophilia have continued. Alternative 
FVIIIa mimetics are in development, with new alternative binding antibodies similar to emicizumab 
showing evidence of FXa generation (Leksa et al. 2017). With the success of antithrombin targeting 
therapy in clinical trials, Ayme et al. have created anti-AT nanobodies with high binding affinity, 
which in a haemophilia knockout murine model have blocked AT activity by 50-100% and normalised 
thrombin generation. The potential of nanobodies with their short transgenic sequences could be 
used in AAV gene therapy approaches to permanently lower antithrombin levels (Ayme et al. 2017).  
Polderijk et al. have alternatively targeted a different aspect of the anticoagulant pathway by using a 
modified 1-antitrypsin to inhibit activated protein C which showed restoration of thrombin 
generation in three separate mouse models (Polderdijk et al. 2017).  
Thirdly, modifications to clotting factors to produce hyperfunctional variants may reduce frequency 
of intravenous injection or enable subcutaneous administration instead. A variant of FIX termed 
CB2679d was developed by Levy et al. with increased affinity for FVIIIa and resistance to AT 
inhibition, resulting in 20-fold potency increase in vitro and in a haemophilia B dog model in 
comparison with wild type FIX (Levy et al. 2017).  
 
Conclusion 
Treatment for haemophilia in the coming years is entering a revolutionary phase, with the advent of 
multiple treatments coming to market such that factor replacement soon will no longer be the sole 
option. Approved extended half-life factor concentrates have started to improve the quality of life of 
patients through reducing injection frequency. Emerging non-factor therapies in trial have potential 
to alter significantly the management of patients in the medium term, as clinicians and patients now 
face the prospect of having many more choices for treating haemophilia and tailoring it to needs and 
lifestyle of individual patients, with each of the therapies targeting different unmet needs in the 
haemophilia population. These treatments already significantly change the management of patients 
with inhibitors and offer more convenient choices for non-inhibitor patients with subcutaneous 
injections on a less frequent basis. Gene therapy offers potential for cure by means of a single 
treatment. Furthermore, in resource limited settings where access to healthcare and factor 
concentrates is inconsistent, it has obvious advantages. However, it will undoubtedly incur a high cost 
for initial treatment.  
Despite the number of novel therapies in the haemophilia field, standard half-life factor concentrate 
will remain as a mainstay of treatment over the next years given that these are familiar to patients 
and have extensive safety data, predictability and ease of monitoring efficacy by using factor assays. 
For most patients, these treatments are highly effective and they may not feel compelled to alter their 
treatment to the newer products.  
Overall, the emergence of agents with novel modes of action now in Phase 3 trials shows that new 
treatments are coming ever closer to marketing approval, bringing with them the prospect of highly 
individualised care in haemophilia as part of the treatment conversation to achieve optimal 
management that patients and their clinicians wish to achieve.   
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